Pfizer cancels partnership with Danish biotech
US drug giant Pfizer has canceled its collaboration with a Danish biotech group concerning development of new CNS treatments. The company is now on the lookout for a new partner for the project, its CEO says.
BY LONNI LYNGE
US-based pharmaceutical group Pfizer has pulled the plug on its partnership with the Danish-based, Swedish-listed biotech company Saniona. According to Saniona CEO Jørgen Drejer, the decision is tied to a major restructuring in Pfizer.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Biotech initiates partnership search immediately
For abonnenter
Biogen leads USD 17m investment in Saniona spin-off
For abonnenter
“I‘m certainly not bitter, but maybe a bit disappointed”
For abonnenter
